Clinical Profile of Ioversol

Floriani, Irene; Ciceri, M.; Torri, Valter; Tinazzi, Angelo; Jahn, Hanns-Peter; Noseda, André

doi:10.1097/00004424-199608000-00003

Investigative Radiology

1996

DOI: 10.1097/00004424-199608000-00003

|View full text |Cite

Clinical Profile of Ioversol

Irene Floriani¹,

M. Ciceri

Valter Torri

et al.

Abstract: Based on these findings, the high-contrast efficacy and patient tolerance make ioversol a suitable agent, equivalent to other nonionic contrast media.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

2012

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Iopentol (Imagopaque®) in vascular procedures A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 3,587 patients in Germany

Muth

Henseke²,

Grynne³

1997

Eur Radiol

View full text Add to dashboard Cite

The aims of the present open, non-comparative survey were to study the safety and efficacy of iopentol (Imagopaque, Nycomed Imaging AS, Oslo, Norway) in a large patient group. In a series of German centres, 3,587 patients underwent various contrast-enhanced examinations with iopentol. The most frequent examinations were computed tomography (CT) (1,740), phlebography (462), and digital subtraction angiography (DSA) (493). Only 82 patients (2.3%) experienced one or more adverse events. Sixty-one (1.7%) of these events were possibly or probably caused by the contrast medium. A total of 111 adverse events were registered, 54 of mild, 42 of moderate and 12 of strong intensity, and 51 events required treatment. The most frequent adverse events were nausea (34), erythema (14) urticaria (9), taste sensation (6), circulatory reactions (5) and angina pectoris (5). The frequencies of adverse events were 2.9% in CT, 2.0% in DSA, 2.0% in phlebography, 1.6% in cardioangiography, and 0.4% in urography. Patients with arteriosclerosis, an earlier contrast medium reaction, multimorbidity or age over 70 years had a statistically significantly higher risk of experiencing an adverse event. Patient tolerance was very good; the mean score was 83% on a visual analogue scale (VAS) ranging from extremely bad (0%) to extremely good (100%). Efficacy, as measured on VAS, was determined. Technical quality was scored as 80%, contrast enhancement within the vessels as 80% and delineation of lesions as 79%. The results from this large patient population confirms the experience from clinical practice that iopentol is a safe, well tolerated and efficient contrast medium.

show abstract

Iopentol (Imagopaque®) in vascular procedures A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 3,587 patients in Germany

Muth

Henseke²,

Grynne³

1997

Eur Radiol

View full text Add to dashboard Cite

show abstract

Development of a life-threatening anaphylactoid reaction following administration of ioversol in a child

Zuckerman

Riess

Patel

et al. 1999

Pediatric Radiology

View full text Add to dashboard Cite

We report for the first time the case of a 3-year-old girl who developed a severe anaphylactoid reaction following the administration of the nonionic, low osmolar intravenous radiographic contrast agent ioversol. Severe reactions to ioversol have rarely been reported in adult patients and to our knowledge never in children. Health care providers managing children who may require radiologic imaging studies with ioversol should be aware of the potential complications of this radiographic contrast agent.

show abstract

An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations

2012

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical Profile of Ioversol

Abstract: Based on these findings, the high-contrast efficacy and patient tolerance make ioversol a suitable agent, equivalent to other nonionic contrast media.

Cited by 4 publications

References 24 publications

Iopentol (Imagopaque®) in vascular procedures A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 3,587 patients in Germany

Iopentol (Imagopaque®) in vascular procedures A multi-centre monitoring trial assessing adverse events and diagnostic information – results from 3,587 patients in Germany

Development of a life-threatening anaphylactoid reaction following administration of ioversol in a child

An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations

Contact Info

Product

Resources

About